| abstract |
The present invention relates to a pyrazine compound of formula I where: R1 is optionally substituted C3-C8 cycloalkyl, C3-C6 heterocyclyl or C1-C10 heteroaryl; when X1 is N, X2 is N or CH and Z is C1-C6 alkylene, C1-C6 haloalkylene, among others and when X1 is CH, X2 is N and Z is C1-C6 haloalkylene, -O-, among others; q, s and p are 0.1 or 2; ; r is 1 or 2; R2 is -OR5 or -NR6R7; R3 is C1-C6 alkyl, C3-C8 cycloalkyl, among others; R4 is optionally substituted C1-C6 alkyl, cyano, among others, R5 is C1-C6 alkyl or C3-C8 cycloalkyl; R6 is H or C1-C6 alkyl; R7 is optionally substituted C1-C6 alkyl, C3-C8 cycloalkyl, among others. It also refers to a pharmaceutical composition. Said compounds modulate the G protein-coupled receptor 6 (GPR6), being useful in the treatment of neurological and psychiatric disorders. |